Drug Trial Radar · NCT02656173
A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
568
Actual
Start
Jan 25, 2016
Primary completion
Jul 21, 2017
Study completion Jul 21, 2017
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma Singapore Pte. Ltd.
- First posted
- Jan 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.
Conditions
- Overactive Bladder
Interventions
MirabegronDrug
Oral tablet
PlaceboDrug
Oral tablet
TamsulosinDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to End of Treatment (EoT) in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and EoT (up to 12 weeks)
- Change From Baseline to Weeks 4, 8, 12 in Mean Number of Micturitions Per 24 HoursTime frame: Baseline and week 4, 8 and 12
Locations
58 sites in 2 countries. Site status is shown where the registry gives one.
Site JP81046
Aichi, Japan
Site JP81009
Chiba, Japan
Site JP81045
Chiba, Japan
Site JP81041
Fukuoka, Japan
Site JP81042
Fukuoka, Japan
Site JP81043
Fukuoka, Japan
Site JP81044
Fukuoka, Japan
Site JP81048
Fukuoka, Japan
Site JP81004
Gunma, Japan
Site JP81005
Gunma, Japan
Site JP81001
Hokkaido, Japan
Site JP81002
Hokkaido, Japan
Site JP81003
Hokkaido, Japan
Site JP81038
Hyōgo, Japan
Site JP81039
Hyōgo, Japan
Site JP81040
Hyōgo, Japan
Site JP81024
Kanagawa, Japan
Site JP81056
Kanagawa, Japan
Site JP81051
Kochi, Japan
Site JP81052
Kochi, Japan
Site JP81047
Kumamoto, Japan
Site JP81025
Osaka, Japan
Site JP81026
Osaka, Japan
Site JP81027
Osaka, Japan
Site JP81028
Osaka, Japan
Site JP81029
Osaka, Japan
Site JP81030
Osaka, Japan
Site JP81031
Osaka, Japan
Site JP81032
Osaka, Japan
Site JP81033
Osaka, Japan
Site JP81034
Osaka, Japan
Site JP81035
Osaka, Japan
Site JP81036
Osaka, Japan
Site JP81037
Osaka, Japan
Site JP81053
Osaka, Japan
Site JP81054
Osaka, Japan
Site JP81006
Saitama, Japan
Site JP81007
Saitama, Japan
Site JP81008
Saitama, Japan
Site JP81050
Shizuoka, Japan
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.